Physician profile
Ender A Akan
NPI 1487658282
$295,744.94
in general payments reported to CMS, 2019-2025
63 companies · $77K in 2025
The $77K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $46K · 2021: $77K · 2022: $31K · 2023: $15K · 2024: $28K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Food and Beverage: $9,012 · Honoraria: $8,800 · Travel and Lodging: $2,447 · Consulting Fee: $1,525 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,487.50 |
| Food and Beverage | $9,012.21 |
| Honoraria | $8,800.00 |
| Travel and Lodging | $2,446.93 |
| Consulting Fee | $1,525.00 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $142,707.21 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $64,567.46 | 2019-2022 | |
| Amgen INC. | $50,087.20 | 2019-2024 | Aimovig |
| Pfizer INC. | $21,049.22 | 2019-2025 | |
| Axsome Therapeutics, INC. | $9,137.18 | 2025 | Symbravo |
| Biogen, INC. | $888.29 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $542.97 | 2020-2024 | Xcopri |
| Lundbeck LLC | $516.71 | 2019-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $477.54 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $374.99 | 2019-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $348.66 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Novartis Pharmaceuticals Corporation | $346.34 | 2019-2024 | |
| Neurelis, INC. | $324.30 | 2022-2024 | Valtoco |
| Ucb, INC. | $297.43 | 2019-2025 | Briviact |
| Neurocrine Biosciences, INC. | $288.35 | 2019-2025 | Ingrezza, Ongentys |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ender Akan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.